

ASX Announcement

Cleansing Statement

Notice under section 708A(5)(e) of the Corporations Act

SYDNEY, TUESDAY 19 DECEMBER 2017: Cellmid Limited (ASX: CDY) notifies, in accordance with section 708A(5)(e) of the Corporations Act, the details required under section 708A(6) in relation to the issue of securities.

Details of the securities issued:

Class of securities: Fully paid ordinary shares

ASX Code of the securities: CDY

Date of issue: 19 December 2017

Total number issued: 3,489,473 Issue price: \$0.38 per share

An Appendix 3B for the above securities was given to the ASX today.

Cellmid advises that:

- (a) the above securities were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) as at the date of this notice, Cellmid has complied with the provisions of Chapter 2M, and section 674, of the Corporations Act as they apply to Cellmid; and
- (c) as at the date of this notice, there is no information that is excluded information within the meaning of sections 708A(7) and 708A(8) of the Corporations Act, being information that:
 - (1) has been excluded from a continuous disclosure notice in accordance with the Listing Rules of ASX; and
 - (2) investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - (A) the assets and liabilities, financial position and performance, profits and losses and prospects of Cellmid; or
 - (B) the rights and liabilities attaching to the shares or generally to the ordinary shares in the capital of Cellmid.

Contact:

Mr Raymond Ting Company Secretary T +612 9221 6830

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

Cellm	iid Limited	
ABN	. 304 119	
09 111	. 304 119	
We (tl	ne entity) give ASX the following	g information.
	1 - All issues st complete the relevant sections (attac	h sheets if there is not enough space).
1	⁺ Class of ⁺ securities issued or to be issued	Fully Paid Ordinary Shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	3,489,473 Ordinary Shares
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Shares - Terms as per as existing ordinary shares

Name of entity

04/03/2013 Appendix 3B Page 1

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$0.38 Ordinary Shares
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Ordinary Shares Working capital for the Company's US Expansion and growth in Australia
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	
6c	Number of *securities issued without security holder approval under rule 7.1	

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A		
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)		
6f	Number of *securities issued under an exception in rule 7.2		
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.		
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements		
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements		
7	⁺ Issue dates	19 December 2017	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.		
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	Number 56,912,357	+Class Ordinary Shares

o4/o3/2013 Appendix 3B Page 3

⁺ See chapter 19 for defined terms.

9	Number and +class of all
	*securities not quoted on ASX
	(including the *securities in
	section 2 if applicable)

Number	⁺ Class
200,0	000 OPT 80c Exp 01.08.2018
200,0	000 OPT \$1 Exp 01.08.2018
500,0	000 OPT \$1.2 Exp 01.08.2018
575,0	000 OPT \$1.2 Exp 19.11.2018
25,00	00 OPT 62c Exp 19.11.2018
100,0	000 OPT 60c Exp 31.10.2019
50,0	000 OPT 60c Exp 01.07.2020

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Unchanged			

Part 2 - Pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
	_	
13	Ratio in which the *securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
	•	
17	Policy for deciding entitlements in relation to fractions	
	•	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
	_	
22	Names of any brokers to the issue	
	_	
23	Fee or commission payable to the broker to the issue	
	A	
24	Amount of any handling fee	
	payable to brokers who lodge acceptances or renunciations on	
	behalf of security holders	
	bendin of security notacis	
25	If the issue is contingent on	
25	security holders' approval, the	
	date of the meeting	
26	Date entitlement and acceptance	
20	form and offer documents will be	
	sent to persons entitled	
	1	
27	If the entity has issued options,	
-/	and the terms entitle option	
	holders to participate on	
	exercise, the date on which	
	notices will be sent to option	
	holders	
28	Date rights trading will begin (if	
	applicable)	
29	Date rights trading will end (if	
	applicable)	
	<u></u>	
30	How do security holders sell	
	their entitlements in full through	
	a broker?	
31	How do security holders sell part	
	of their entitlements through a	
	broker and accept for the	
	balance?	

04/03/2013 Appendix 3B Page 5

⁺ See chapter 19 for defined terms.

Appendix 31	3
New issue a	nnouncement

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	
33	⁺Issu€	e date	
		uotation of securities complete this section if you are applying for quotation of securities	
34	Type (tick o	of *securities one)	
(a)		⁺ Securities described in Part 1	
(b)		All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entitie	es tha	t have ticked box 34(a)	
Addit	ional	securities forming a new class of securities	
Tick to docume		e you are providing the information or	
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	
37		A copy of any trust deed for the additional *securities	

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)			
38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do		
	 the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Ivanibei	Ciass

o4/o3/2013 Appendix 3B Page 7

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Director/Company secretary)

prais falan

Date: 19 December 17

Print name: Maria Halasz

== == == ==

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	53,193,351 (1,063,867,011*) *Pre-consolidation number			
Add the following:				
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2	97,500 (1,950,000*) Ordinary shares (Under Employee Share Plan) Issued Date:1/03/2017			
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval	103,704 (2,074,074*) Ordinary shares (Under Employee Share Plan) Issued Date:12/05/2017			
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period	50,000 (1,000,000*) Unlisted options (Under Employee Share Plan) Issued Date:16/11/2017			
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 				
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	200,000 (4,000,000*)			
"A"	53,244,555 (1,064,891,085*)			

o4/o3/2013 Appendix 3B Page 9

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	7,986,684 (159,733,663*)
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used	
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	228,261 (4,565,218*) (Ordinary Shares issued on conversion of interest payable)
 Under an exception in rule 7.2 	
• Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	228,261 (4,565,218*)
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1	
"A" x 0.15	7,986,684 (159,733,663*)
Note: number must be same as shown in Step 2	
Subtract "C"	228,261 (4,565,218*)
Note: number must be same as shown in Step 3	
Total ["A" x 0.15] – "C"	7,758,423 (155,168,445*) [Note: this is the remaining placement capacity under rule 7.1

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.